SPARC reports positive results from Phase 3 trial of ocular hypertension treatment

Published On 2021-05-16 04:30 GMT   |   Update On 2021-05-16 04:30 GMT
Advertisement

MumbaiSun Pharma Advanced Research Company Ltd. (SPARC) has recently reported positive top-line results from its Phase 3 trial (CLR_16_33) for its investigational drug, PDP-716 ophthalmic suspension, for the treatment of Open Angle Glaucoma or Ocular Hypertension.

The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day. 

Advertisement

The primary endpoint of the trial was to evaluate the efficacy of once daily (QD) dosing of PDP-716 0.35% compared with Alphagan P 0.1% dosed 3 times a day (TID) in subjects with open-angle glaucoma or ocular hypertension. Equivalence in intraocular pressure was demonstrated across all 9 required timepoints, showing that the 2 formulations of brimonidine are functionally equivalent.

The safety of once daily (QD) dosing of PDP-716 compared with Alphagan P 0.1% dosed 3 times a day (TID) was also evaluated. Treatment emergent adverse events were similar with 38.8% in the PDP-716 group vs. 33.2% with Alphagan P 0.1% group.

"We are very pleased by these results for PDP-716. Once daily dosing of PDP-716 can significantly reduce the dosing frequency compared to currently marketed formulation and can have positive impact on quality of life for patients with Glaucoma. On behalf of everyone at SPARC, I would like to extend my sincere gratitude to the patients, families and investigators involved in this study." said Anil Raghavan, CEO of SPARC.

Read also: SPARC investigational drug shows promise in phase 3 trial for treating inflammation, pain related to ocular surgery

PDP-716 is a novel, once daily, ophthalmic suspension of Brimonidine Tartrate 0.35%. PDP-716 is developed using SPARC's proprietary TearActTM technology.
CLR_16_33 is randomized, multi-center, investigator-masked, parallel group, equivalence study of once daily PDP-716 0.35% ophthalmic suspension compared with 3 times a day Alphagan P 0.1% in subjects with open angle glaucoma or ocular hypertension.



Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News